Literature DB >> 11836557

Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.

Gene Hung1, Xiankui Li, Rodolfo Faudoa, Zhu Xeu, Lan Kluwe, Johng S Rhim, William Slattery, David Lim.   

Abstract

By using retroviral mediated gene transfer technique, a primary schwannoma culture from a 56-year-old Neurofibromatosis type 2 (NF2) patient was immortalized with HPV E6-E7 genes. This cell line, HEI193, has a unique splice site mutation of the NF2 gene. Both immunocytochemistry and molecular biology techniques were used to demonstrate that this cell line is of Schwann cell origin. Comparison of the primary tumor with HEI193 revealed the same NF2 mutation and an identical pattern of allele loss at multiple loci, indicating that the established cell line had maintained many of the properties of the original tumor. The immortalized cell line was non-tumorigenic in both severe combined immunodeficient (SCID) mice and nude mice, but has altered growth properties such as higher proliferation rate and independence of Schwann cell growth factors. To our knowledge, this is the first attempt to establish permanent cell lines from human NF2 patients. This Schwann tumor-derived cell line may provide a useful model system for the study of familial NF2 tumor pathogenesis, for elucidating NF2 functions and for testing new gene-based therapeutic approaches.

Entities:  

Mesh:

Year:  2002        PMID: 11836557

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  31 in total

1.  Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.

Authors:  Sherif G Ahmed; Ahmed Abdelnabi; Casey A Maguire; Mohamed Doha; Jessica E Sagers; Rebecca M Lewis; Alona Muzikansky; Marco Giovannini; Anat Stemmer-Rachamimov; Konstantina M Stankovic; Giulia Fulci; Gary J Brenner
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

Review 2.  Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma.

Authors:  Justin Hall; Shilpa Prabhakar; Leonora Balaj; Charles P Lai; Richard A Cerione; Xandra O Breakefield
Journal:  Cell Mol Neurobiol       Date:  2016-03-26       Impact factor: 5.046

3.  Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.

Authors:  Hon-Kit Wong; Akio Shimizu; Nathaniel D Kirkpatrick; Igor Garkavtsev; Annie W Chan; Emmanuelle di Tomaso; Michael Klagsbrun; Rakesh K Jain
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

4.  Developing myelin specific promoters for schwannoma gene therapy.

Authors:  Sherif G Ahmed; Farnaz Hadaegh; Gary J Brenner
Journal:  J Neurosci Methods       Date:  2019-05-22       Impact factor: 2.390

5.  Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Authors:  Sonam Dilwali; Martijn C Briët; Shyan-Yuan Kao; Takeshi Fujita; Lukas D Landegger; Michael P Platt; Konstantina M Stankovic
Journal:  Mol Oncol       Date:  2015-03-31       Impact factor: 6.603

6.  Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas.

Authors:  Alizée Boin; Anne Couvelard; Christophe Couderc; Isabel Brito; Dan Filipescu; Michel Kalamarides; Pierre Bedossa; Leanne De Koning; Carine Danelsky; Thierry Dubois; Philippe Hupé; Daniel Louvard; Dominique Lallemand
Journal:  Neuro Oncol       Date:  2014-02-20       Impact factor: 12.300

7.  Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells.

Authors:  Vitor Y R Soares; Nadia A Atai; Takeshi Fujita; Sonam Dilwali; Sarada Sivaraman; Lukas D Landegger; Fred H Hochberg; Carlos A P C Oliveira; Fayez Bahmad; Xandra O Breakefield; Konstantina M Stankovic
Journal:  Neuro Oncol       Date:  2016-05-18       Impact factor: 12.300

8.  Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

Authors:  S Prabhakar; G J Brenner; B Sung; S M Messerli; J Mao; M Sena-Esteves; A Stemmer-Rachamimov; B Tannous; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2009-10-16       Impact factor: 5.987

9.  Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein.

Authors:  Deborah N Chadee; Dazhong Xu; Gene Hung; Ali Andalibi; David J Lim; Zhijun Luo; David H Gutmann; John M Kyriakis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

10.  Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.

Authors:  Jianman Guo; Katherine E Chaney; Kwangmin Choi; Gabriela Witek; Ami V Patel; Hong Xie; Danny Lin; Kanupriya Whig; Yao Xiong; David C Schultz; Nancy Ratner; Jeffrey Field
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.